PUBLICATIONS
Cho et al., Nat Biomed Eng. 2021 Aug;5(8):880-896.
Nat Biomed Eng. 2021 Aug;5(8):880-896. doi: 10.1038/s41551-021-00783-0. Epub 2021 Aug 23.
PMID: 34426676
Fibroblasts can be directly reprogrammed into cardiomyocytes, endothelial cells or smooth muscle cells. Here we report the reprogramming of mouse tail-tip fibroblasts simultaneously into cells resembling these three cell types using the microRNA mimic miR-208b-3p, ascorbic acid and bone morphogenetic protein 4, as well as the formation of tissue-like structures formed by the directly reprogrammed cells. Implantation of the formed cardiovascular tissue into the infarcted hearts of mice led to the migration of reprogrammed cells to the injured tissue, reducing regional cardiac strain and improving cardiac function. The migrated endothelial cells and smooth muscle cells contributed to vessel formation, and the migrated cardiomyocytes, which initially displayed immature characteristics, became mature over time and formed gap junctions with host cardiomyocytes. Direct reprogramming of somatic cells to make cardiac tissue may aid the development of applications in cell therapy, disease modelling and drug discovery for cardiovascular diseases.
Lee et al., Circulation. 2017 Nov 14;136(20):1939-1954.
Enhanced Therapeutic and Long-Term Dynamic Vascularization Effects of Human Pluripotent Stem Cell-Derived Endothelial Cells Encapsulated in a Nanomatrix Gel.
Lee SJ, Sohn YD, Andukuri A, Kim S, Byun J, Han JW, Park IH, Jun HW, Yoon YS.
Circulation. 2017 Nov 14;136(20):1939-1954. doi: 10.1161/CIRCULATIONAHA.116.026329. Epub 2017 Sep 29.
PMID: 28972000
Human pluripotent stem cell (hPSC)-derived endothelial cells (ECs) have limited clinical utility because of undefined components in the differentiation system and poor cell survival in vivo. Here, we aimed to develop a fully defined and clinically compatible system to differentiate hPSCs into ECs. Furthermore, we aimed to enhance cell survival, vessel formation, and therapeutic potential by encapsulating hPSC-ECs with a peptide amphiphile (PA) nanomatrix gel. We induced differentiation of hPSCs into the mesodermal lineage by culturing on collagen-coated plates with a glycogen synthase kinase 3β inhibitor. Next, vascular endothelial growth factor, endothelial growth factor, and basic fibroblast growth factor were added for endothelial lineage differentiation, followed by sorting for CDH5 (VE-cadherin). We constructed an extracellular matrix-mimicking PA nanomatrix gel (PA-RGDS) by incorporating the cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloproteinase-2-degradable sequence. We then evaluated whether the encapsulation of hPSC-CDH5+ cells in PA-RGDS could enhance long-term cell survival and vascular regenerative effects in a hind-limb ischemia model with laser Doppler perfusion imaging, bioluminescence imaging, real-time reverse transcription-polymerase chain reaction, and histological analysis. The resultant hPSC-derived CDH5+ cells (hPSC-ECs) showed highly enriched and genuine EC characteristics and proangiogenic activities. When injected into ischemic hind limbs, hPSC-ECs showed better perfusion recovery and higher vessel-forming capacity compared with media-, PA-RGDS-, or human umbilical vein EC-injected groups. However, the group receiving the PA-RGDS-encapsulated hPSC-ECs showed better perfusion recovery, more robust and longer cell survival (> 10 months), and higher and prolonged angiogenic and vascular incorporation capabilities than the bare hPSC-EC-injected group. Surprisingly, the engrafted hPSC-ECs demonstrated previously unknown sustained and dynamic vessel-forming behavior: initial perivascular concentration, a guiding role for new vessel formation, and progressive incorporation into the vessels over 10 months. We generated highly enriched hPSC-ECs via a clinically compatible system. Furthermore, this study demonstrated that a biocompatible PA-RGDS nanomatrix gel substantially improved long-term survival of hPSC-ECs in an ischemic environment and improved neovascularization effects of hPSC-ECs via prolonged and unique angiogenic and vessel-forming properties. This PA-RGDS-mediated transplantation of hPSC-ECs can serve as a novel platform for cell-based therapy and investigation of long-term behavior of hPSC-ECs.
Lee et al., Circ Res. 2017 Mar 3;120(5):848-861.
Direct Reprogramming of Human Dermal Fibroblasts Into Endothelial Cells Using ER71/ETV2.
Lee S, Park C, Han JW, Kim JY, Cho K, Kim EJ, Kim S, Lee SJ, Oh SY, Tanaka Y, Park IH, An HJ, Shin CM, Sharma S, Yoon YS.
Circ Res. 2017 Mar 3;120(5):848-861. doi: 10.1161/CIRCRESAHA.116.309833. Epub 2016 Dec 21.
PMID: 28003219
Direct conversion or reprogramming of human postnatal cells into endothelial cells (ECs), bypassing stem or progenitor cell status, is crucial for regenerative medicine, cell therapy, and pathophysiological investigation but has remained largely unexplored. We sought to directly reprogram human postnatal dermal fibroblasts to ECs with vasculogenic and endothelial transcription factors and determine their vascularizing and therapeutic potential. We utilized various combinations of 7 EC transcription factors to transduce human postnatal dermal fibroblasts and found that ER71/ETV2 (ETS variant 2) alone best induced endothelial features. KDR+ (kinase insert domain receptor) cells sorted at day 7 from ER71/ETV2-transduced human postnatal dermal fibroblasts showed less mature but enriched endothelial characteristics and thus were referred to as early reprogrammed ECs (rECs), and did not undergo maturation by further culture. After a period of several weeks’ transgene-free culture followed by transient reinduction of ER71/ETV2, early rECs matured during 3 months of culture and showed reduced ETV2 expression, reaching a mature phenotype similar to postnatal human ECs. These were termed late rECs. While early rECs exhibited an immature phenotype, their implantation into ischemic hindlimbs induced enhanced recovery from ischemia. These 2 rECs showed clear capacity for contributing to new vessel formation through direct vascular incorporation in vivo. Paracrine or proangiogenic effects of implanted early rECs played a significant role in repairing hindlimb ischemia. This study for the first time demonstrates that ER71/ETV2 alone can directly reprogram human postnatal cells to functional, mature ECs after an intervening transgene-free period. These rECs could be valuable for cell therapy, personalized disease investigation, and exploration of the reprogramming process.
Cakir et al., Nat Methods, 2019 Nov;16(11):1169-1175.
Engineering of human brain organoids with a functional vascular-like system.
Cakir B, Xiang Y, Tanaka Y, Kural MH, Parent M, Kang YJ, Chapeton K, Patterson B, Yuan Y, He CS, Raredon MSB, Dengelegi J, Kim KY, Sun P, Zhong M, Lee S, Patra P, Hyder F, Niklason LE, Lee SH, Yoon YS, Park IH.
Nat Methods. 2019 Nov;16(11):1169-1175. doi: 10.1038/s41592-019-0586-5. Epub 2019 Oct 7.
PMID: 31591580
Human cortical organoids (hCOs), derived from human embryonic stem cells (hESCs), provide a platform to study human brain development and diseases in complex three-dimensional tissue. However, current hCOs lack microvasculature, resulting in limited oxygen and nutrient delivery to the inner-most parts of hCOs. We engineered hESCs to ectopically express human ETS variant 2 (ETV2). ETV2-expressing cells in hCOs contributed to forming a complex vascular-like network in hCOs. Importantly, the presence of vasculature-like structures resulted in enhanced functional maturation of organoids. We found that vascularized hCOs (vhCOs) acquired several blood-brain barrier characteristics, including an increase in the expression of tight junctions, nutrient transporters and trans-endothelial electrical resistance. Finally, ETV2-induced endothelium supported the formation of perfused blood vessels in vivo. These vhCOs form vasculature-like structures that resemble the vasculature in early prenatal brain, and they present a robust model to study brain disease in vitro.
Lee et al., Biomaterials. 2015 Sep;63:158-67.
Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes.
Lee S, Valmikinathan CM, Byun J, Kim S, Lee G, Mokarram N, Pai SB, Um E, Bellamkonda RV, Yoon YS.
Biomaterials. 2015 Sep;63:158-67. doi: 10.1016/j.biomaterials.2015.06.009. Epub 2015 Jun 11.
PMID: 26102992
Various stem cells and their progeny have been used therapeutically for vascular regeneration. One of the major hurdles for cell-based therapy is low cell retention in vivo, and to improve cell survival several biomaterials have been used to encapsulate cells before transplantation. Vascular regeneration involves new blood vessel formation which consists of two processes, vasculogenesis and angiogenesis. While embryonic stem cell (ESC)-derived endothelial cells (ESC-ECs) have clearer vasculogenic potency, adult cells exert their effects mainly through paracrine angiogenic activities. While these two cells have seemingly complementary advantages, there have not been any studies to date combining these two cell types for vascular regeneration. We have developed a novel chitosan-based hydrogel construct that encapsulates both CD31-expressing BM-mononuclear cells (BM-CD31(+) cells) and ESC-ECs, and is loaded with VEGF-releasing microtubes. This cell construct showed high cell survival and minimal cytotoxicity in vitro. When implanted into a mouse model of hindlimb ischemia, it induced robust cell retention, neovascularization through vasculogenesis and angiogenesis, and efficiently induced recovery of blood flow in ischemic hindlimbs. This chitosan-based hydrogel encapsulating mixed adult and embryonic cell derivatives and containing VEGF can serve as a novel platform for treating various cardiovascular diseases.
Lee et al., Sci Rep. 2015 Jun 12;5:11019.
Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair.
Lee SJ, Park C, Lee JY, Kim S, Kwon PJ, Kim W, Jeon YH, Lee E, Yoon YS.
Sci Rep. 2015 Jun 12;5:11019. doi: 10.1038/srep11019.
PMID: 26066093
Human pluripotent stem cells (hPSCs) have emerged as an important source for cell therapy. However, to date, no studies demonstrated generation of purified hPSC-derived lymphatic endothelial cells (LECs) and tested their therapeutic potential in disease models. Here we sought to differentiate hPSCs into the LEC lineage, purify them with LEC markers, and evaluate their therapeutic effects. We found that an OP9-assisted culture system reinforced by addition of VEGF-A, VEGF-C, and EGF most efficiently generated LECs, which were then isolated via FACS-sorting with LYVE-1 and PODOPLANIN. These hPSC-derived LYVE-1(+)PODOPLANIN(+)cells showed a pure committed LEC phenotype, formed new lymphatic vessels, and expressed lymphangiogenic factors at high levels. These hPSC-derived LECs enhanced wound healing through lymphangiogenesis and lymphvasculogenesis. Here we report, for the first time, that LECs can be selectively isolated from differentiating hPSCs, and that these cells are potent for lymphatic vessel formation in vivo and wound healing. This system and the purified hPSC-derived LECs can serve as a new platform for studying LEC development as well as for cell therapy.
Shin et al., Circ Res. 2019 Dec 6;125(12):1141-1145.
Current State of Cardiovascular Research in Korea.
Shin JI, Oh J, Kim HC, Choi D, Yoon YS.
Circ Res. 2019 Dec 6;125(12):1141-1145. doi: 10.1161/CIRCRESAHA.119.310859. Epub 2019 Dec 5.
PMID: 31804914
Cardiovascular diseases have shown a continuous increase in Korea over the past decade and became the second most common cause of mortality in Korea. Although the number and the amount of total grants for cardiovascular research have increased in Korea, the proportion of the number of grants and total amount allocated for the cardiac/cardiovascular field to all health and medical research fields has not changed much over this period. In addition, the publications related to clinical research have substantially increased in Korea along with the number of nation-wide registries for cardiovascular diseases, but basic and translational research did not show significant growth, requiring new measures to promote basic and translational cardiovascular research in Korea.
Lee et al., Circ Res. 2019 Jan 4;124(1):29-31.
Vascular Regeneration With New Sources of Endothelial Cells.
Lee S, Lee SJ, Yoon YS.
Circ Res. 2019 Jan 4;124(1):29-31. doi: 10.1161/CIRCRESAHA.118.314195.
PMID: 30605418
Two new sources of ECs were generated from human induced pluripotent stem cells (hiPSCs), and by direct reprogramming of somatic cells without undergoing the stages of stem or progenitor cell. These two types of ECs will advance our understanding of EC biology and can become a novel therapeutic option for treating ischemic cardiovascular diseases.
Lee et al., Curr Cardiol Rep. 2018 May 5;20(6):45.
Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility.
Lee SJ, Kim KH, Yoon YS.
Curr Cardiol Rep. 2018 May 5;20(6):45. doi: 10.1007/s11886-018-0985-8.
PMID: 29730842
Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.
Lee et al., Regen Med. 2017 Apr;12(4):317-320.
Direct reprogramming into endothelial cells: a new source for vascular regeneration.
Lee S, Kim JE, Johnson BA, Andukuri A, Yoon YS.
Regen Med. 2017 Apr;12(4):317-320. doi: 10.2217/rme-2017-0022. Epub 2017 Jun 16.
PMID: 28621172
Despite significant efforts over the last several decades, treating patients with severe conditions of myocardial ischemia and peripheral vascular disease remains challenging. For example, critical limb ischemia, a severe form of peripheral vascular disease, can lead to a 50% risk of amputation with high incidences of second-leg loss and mortality within 2–5 years after the first amputation. Pathophysiologically, the main cause of these clinical entities is the loss or dysfunction of blood vessels, of which the major component is endothelial cells (ECs). Thus, therapeutic neovascularization has emerged as an attractive approach to re-establish functional vasculature, which can support proper blood perfusion and tissue repair.
| 1. | Regeneration of infarcted mouse hearts by cardiovascular tissue formed via the direct reprogramming of mouse fibroblasts.
Cho J, Kim S, Lee H, Rah W, Cho HC, Kim NK, Bae S, Shin DH, Lee MG, Park IH, Tanaka Y, Shin E, Yi H, Han JW, Hwang PTJ, Jun HW, Park HJ, Cho K, Lee SW, Jung JK, Levit RD, Sussman MA, Harvey RP, Yoon YS. Nat Biomed Eng. 2021 Aug;5(8):880-896. doi: 10.1038/s41551-021-00783-0. Epub 2021 Aug 23. PMID: 34426676 |
| 2. | Reduced angiovasculogenic and increased inflammatory profiles of cord blood cells in severe but not mild preeclampsia.
Cho S, Sohn YD, Kim S, Rajakumar A, Badell ML, Sidell N, Yoon YS. Sci Rep. 2021 Feb 11;11(1):3630. doi: 10.1038/s41598-021-83146-8. PMID: 33574435 Free PMC article. |
| 3. | Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.
Chen J, Zhang X, Millican R, Sherwood J, Martin S, Jo H, Yoon YS, Brott BC, Jun HW. Adv Drug Deliv Rev. 2021 Mar;170:142-199. doi: 10.1016/j.addr.2021.01.005. Epub 2021 Jan 9. PMID: 33428994Review. |
| 4. | Mammalian CBX7 isoforms p36 and p22 exhibit differential responses to serum, varying functions for proliferation, and distinct subcellular localization.
Cho KW, Andrade M, Zhang Y, Yoon YS. Sci Rep. 2020 May 15;10(1):8061. doi: 10.1038/s41598-020-64908-2. PMID: 32415167 Free PMC article. |
| 5. | Current State of Cardiovascular Research in Korea.
Shin JI, Oh J, Kim HC, Choi D, Yoon YS. Circ Res. 2019 Dec 6;125(12):1141-1145. doi: 10.1161/CIRCRESAHA.119.310859. Epub 2019 Dec 5. PMID: 31804914 Free PMC article. |
| 6. | Engineering of human brain organoids with a functional vascular-like system.
Cakir B, Xiang Y, Tanaka Y, Kural MH, Parent M, Kang YJ, Chapeton K, Patterson B, Yuan Y, He CS, Raredon MSB, Dengelegi J, Kim KY, Sun P, Zhong M, Lee S, Patra P, Hyder F, Niklason LE, Lee SH, Yoon YS, Park IH. Nat Methods. 2019 Nov;16(11):1169-1175. doi: 10.1038/s41592-019-0586-5. Epub 2019 Oct 7. PMID: 31591580 Free PMC article. |
| 7. | Vascular Regeneration With New Sources of Endothelial Cells.
Lee S, Lee SJ, Yoon YS. Circ Res. 2019 Jan 4;124(1):29-31. doi: 10.1161/CIRCRESAHA.118.314195. PMID: 30605418 Free PMC article. |
| 8. | High-resolution acoustophoretic 3D cell patterning to construct functional collateral cylindroids for ischemia therapy.
Kang B, Shin J, Park HJ, Rhyou C, Kang D, Lee SJ, Yoon YS, Cho SW, Lee H. Nat Commun. 2018 Dec 20;9(1):5402. doi: 10.1038/s41467-018-07823-5. PMID: 30573732 Free PMC article. |
| 9. | Big bottlenecks in cardiovascular tissue engineering.
Huang NF, Serpooshan V, Morris VB, Sayed N, Pardon G, Abilez OJ, Nakayama KH, Pruitt BL, Wu SM, Yoon YS, Zhang J, Wu JC. Commun Biol. 2018 Nov 21;1:199. doi: 10.1038/s42003-018-0202-8. eCollection 2018. PMID: 30480100 Free PMC article. |
| 10. | Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes.
Park M, Yoon YS. Korean Circ J. 2018 Nov;48(11):974-988. doi: 10.4070/kcj.2018.0312. PMID: 30334384Free PMC article.Review. |
| 11. | Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility.
Lee SJ, Kim KH, Yoon YS. Curr Cardiol Rep. 2018 May 5;20(6):45. doi: 10.1007/s11886-018-0985-8. PMID: 29730842Free PMC article.Review. |
| 12. | Design of Polymeric Culture Substrates to Promote Proangiogenic Potential of Stem Cells.
Kwon BJ, Wang X, Kang ML, You J, Lee SJ, Kim WS, Yoon YS, Park JC, Sung HJ. Macromol Biosci. 2018 Feb;18(2). doi: 10.1002/mabi.201700340. Epub 2017 Dec 29. PMID: 29285899Review. |
| 13. | Enhanced Therapeutic and Long-Term Dynamic Vascularization Effects of Human Pluripotent Stem Cell-Derived Endothelial Cells Encapsulated in a Nanomatrix Gel.
Lee SJ, Sohn YD, Andukuri A, Kim S, Byun J, Han JW, Park IH, Jun HW, Yoon YS. Circulation. 2017 Nov 14;136(20):1939-1954. doi: 10.1161/CIRCULATIONAHA.116.026329. Epub 2017 Sep 29. PMID: 28972000 Free PMC article. |
| 14. | Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering.
Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JM, Jun HW, Yoon YS, Bursac N, Prabhu SD, Dorn GW 2nd, Bolli R, Kitsis RN, Zhang J. J Am Coll Cardiol. 2017 Aug 8;70(6):766-775. doi: 10.1016/j.jacc.2017.06.012. PMID: 28774384Free PMC article.Review. |
| 15. | Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
Ban K, Bae S, Yoon YS. Theranostics. 2017 May 17;7(7):2067-2077. doi: 10.7150/thno.19427. eCollection 2017. PMID: 28638487Free PMC article.Review. |
| 16. | Direct reprogramming into endothelial cells: a new source for vascular regeneration.
Lee S, Kim JE, Johnson BA, Andukuri A, Yoon YS. Regen Med. 2017 Apr;12(4):317-320. doi: 10.2217/rme-2017-0022. Epub 2017 Jun 16. PMID: 28621172Free PMC article.Review.No abstract available. |
| 17. | Modified Mouse Models of Chronic Secondary Lymphedema: Tail and Hind Limb Models.
Jun H, Lee JY, Kim JH, Noh M, Kwon TW, Cho YP, Yoon YS. Ann Vasc Surg. 2017 Aug;43:288-295. doi: 10.1016/j.avsg.2017.01.023. Epub 2017 May 4. PMID: 28479437 Free PMC article. |
| 18. | Direct Reprogramming of Human Dermal Fibroblasts Into Endothelial Cells Using ER71/ETV2.
Lee S, Park C, Han JW, Kim JY, Cho K, Kim EJ, Kim S, Lee SJ, Oh SY, Tanaka Y, Park IH, An HJ, Shin CM, Sharma S, Yoon YS. Circ Res. 2017 Mar 3;120(5):848-861. doi: 10.1161/CIRCRESAHA.116.309833. Epub 2016 Dec 21. PMID: 28003219 Free PMC article. |
| 19. | Novel Multifunctional Nanomatrix Reduces Inflammation in Dynamic Conditions in Vitro and Dilates Arteries ex Vivo.
Alexander GC, Vines JB, Hwang P, Kim T, Kim JA, Brott BC, Yoon YS, Jun HW. ACS Appl Mater Interfaces. 2016 Mar 2;8(8):5178-87. doi: 10.1021/acsami.6b00565. Epub 2016 Feb 17. PMID: 26849167 Free PMC article. |
| 20. | Non-genetic Purification of Ventricular Cardiomyocytes from Differentiating Embryonic Stem Cells through Molecular Beacons Targeting IRX-4.
Ban K, Wile B, Cho KW, Kim S, Song MK, Kim SY, Singer J, Syed A, Yu SP, Wagner M, Bao G, Yoon YS. Stem Cell Reports. 2015 Dec 8;5(6):1239-1249. doi: 10.1016/j.stemcr.2015.10.021. PMID: 26651608 Free PMC article. |
| 21. | Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair.
Kim SW, Jin HL, Kang SM, Kim S, Yoo KJ, Jang Y, Kim HO, Yoon YS. Int J Cardiol. 2016 Jan 15;203:498-507. doi: 10.1016/j.ijcard.2015.10.110. Epub 2015 Oct 23. PMID: 26551883 Free PMC article. |
| 22. | Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes.
Lee S, Valmikinathan CM, Byun J, Kim S, Lee G, Mokarram N, Pai SB, Um E, Bellamkonda RV, Yoon YS. Biomaterials. 2015 Sep;63:158-67. doi: 10.1016/j.biomaterials.2015.06.009. Epub 2015 Jun 11. PMID: 26102992 Free PMC article. |
| 23. | Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair.
Lee SJ, Park C, Lee JY, Kim S, Kwon PJ, Kim W, Jeon YH, Lee E, Yoon YS. Sci Rep. 2015 Jun 12;5:11019. doi: 10.1038/srep11019. PMID: 26066093 Free PMC article. |
| 24. | Bone Marrow-Derived Mesenchymal Stem Cells Improve Diabetic Neuropathy by Direct Modulation of Both Angiogenesis and Myelination in Peripheral Nerves.
Han JW, Choi D, Lee MY, Huh YH, Yoon YS. Cell Transplant. 2016;25(2):313-26. doi: 10.3727/096368915X688209. Epub 2015 May 13. PMID: 25975801 Free PMC article. |
| 25. | Cultured human bone marrow-derived CD31(+) cells are effective for cardiac and vascular repair through enhanced angiogenic, adhesion, and anti-inflammatory effects.
Kim SW, Houge M, Brown M, Davis ME, Yoon YS. J Am Coll Cardiol. 2014 Oct 21;64(16):1681-94. doi: 10.1016/j.jacc.2014.06.1204. PMID: 25323256 Free PMC article. |
| 26. | Molecular beacon-enabled purification of living cells by targeting cell type-specific mRNAs.
Wile BM, Ban K, Yoon YS, Bao G. Nat Protoc. 2014 Oct;9(10):2411-24. doi: 10.1038/nprot.2014.154. Epub 2014 Sep 18. PMID: 25232937 Free PMC article. |
| 27. | Cell therapy with embryonic stem cell-derived cardiomyocytes encapsulated in injectable nanomatrix gel enhances cell engraftment and promotes cardiac repair.
Ban K, Park HJ, Kim S, Andukuri A, Cho KW, Hwang JW, Cha HJ, Kim SY, Kim WS, Jun HW, Yoon YS. ACS Nano. 2014 Oct 28;8(10):10815-25. doi: 10.1021/nn504617g. Epub 2014 Sep 15. PMID: 25210842 Free PMC article. |
| 28. | Evaluation of the effect of expansion and shear stress on a self-assembled endothelium mimicking nanomatrix coating for drug eluting stents in vitro and in vivo.
Andukuri A, Min I, Hwang P, Alexander G, Marshall LE, Berry JL, Wick TM, Joung YK, Yoon YS, Brott BC, Han DK, Jun HW. Biofabrication. 2014 Sep;6(3):035019. doi: 10.1088/1758-5082/6/3/035019. Epub 2014 Jul 22. PMID: 25048693 Free PMC article. |
| 29. | Diabetic Mesenchymal Stem Cells Are Ineffective for Improving Limb Ischemia Due to Their Impaired Angiogenic Capability.
Kim H, Han JW, Lee JY, Choi YJ, Sohn YD, Song M, Yoon YS. Cell Transplant. 2015;24(8):1571-84. doi: 10.3727/096368914X682792. Epub 2014 Jul 8. PMID: 25008576 Free PMC article. |
| 30. | The modulation of cardiac progenitor cell function by hydrogel-dependent Notch1 activation.
Boopathy AV, Che PL, Somasuntharam I, Fiore VF, Cabigas EB, Ban K, Brown ME, Narui Y, Barker TH, Yoon YS, Salaita K, García AJ, Davis ME. Biomaterials. 2014 Sep;35(28):8103-12. doi: 10.1016/j.biomaterials.2014.05.082. Epub 2014 Jun 25. PMID: 24974008 Free PMC article. |
| 31. | Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.
Poole J, Mavromatis K, Binongo JN, Khan A, Li Q, Khayata M, Rocco E, Topel M, Zhang X, Brown C, Corriere MA, Murrow J, Sher S, Clement S, Ashraf K, Rashed A, Kabbany T, Neuman R, Morris A, Ali A, Hayek S, Oshinski J, Yoon YS, Waller EK, Quyyumi AA. JAMA. 2013 Dec 25;310(24):2631-9. doi: 10.1001/jama.2013.282540. PMID: 24247554Clinical Trial. |
| 32. | Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNA.
Ban K, Wile B, Kim S, Park HJ, Byun J, Cho KW, Saafir T, Song MK, Yu SP, Wagner M, Bao G, Yoon YS. Circulation. 2013 Oct 22;128(17):1897-909. doi: 10.1161/CIRCULATIONAHA.113.004228. Epub 2013 Aug 30. PMID: 23995537 Free PMC article. |
| 33. | Cardiovascular repair with bone marrow-derived cells.
Kim WS, Lee S, Yoon YS. Blood Res. 2013 Jun;48(2):76-86. doi: 10.5045/br.2013.48.2.76. Epub 2013 Jun 25. PMID: 23826576 Free PMC article. |
| 34. | Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency.
Wang T, Wu H, Li Y, Szulwach KE, Lin L, Li X, Chen IP, Goldlust IS, Chamberlain SJ, Dodd A, Gong H, Ananiev G, Han JW, Yoon YS, Rudd MK, Yu M, Song CX, He C, Chang Q, Warren ST, Jin P. Nat Cell Biol. 2013 Jun;15(6):700-11. doi: 10.1038/ncb2748. Epub 2013 May 19. PMID: 23685628 Free PMC article. |
| 35. | Cell therapy for diabetic neuropathy using adult stem or progenitor cells.
Han JW, Sin MY, Yoon YS. Diabetes Metab J. 2013 Apr;37(2):91-105. doi: 10.4093/dmj.2013.37.2.91. PMID: 23641349 Free PMC article. |
| 36. | Oxidative stress-induced Notch1 signaling promotes cardiogenic gene expression in mesenchymal stem cells.
Boopathy AV, Pendergrass KD, Che PL, Yoon YS, Davis ME. Stem Cell Res Ther. 2013 Apr 18;4(2):43. doi: 10.1186/scrt190. PMID: 23597145 Free PMC article. |
| 37. | Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs.
Sohn YD, Somasuntharam I, Che PL, Jayswal R, Murthy N, Davis ME, Yoon YS. Biomaterials. 2013 Jun;34(17):4235-41. doi: 10.1016/j.biomaterials.2013.02.005. Epub 2013 Mar 9. PMID: 23489923 Free PMC article. |
| 38. | Enhanced human endothelial progenitor cell adhesion and differentiation by a bioinspired multifunctional nanomatrix.
Andukuri A, Sohn YD, Anakwenze CP, Lim DJ, Brott BC, Yoon YS, Jun HW. Tissue Eng Part C Methods. 2013 May;19(5):375-85. doi: 10.1089/ten.TEC.2012.0312. Epub 2012 Dec 19. PMID: 23126402 Free PMC article. |
| 39. | Development of a novel two-dimensional directed differentiation system for generation of cardiomyocytes from human pluripotent stem cells.
Moon SH, Ban K, Kim C, Kim SS, Byun J, Song MK, Park IH, Yu SP, Yoon YS. Int J Cardiol. 2013 Sep 20;168(1):41-52. doi: 10.1016/j.ijcard.2012.09.077. Epub 2012 Oct 6. PMID: 23044428 Free PMC article. |
| 40. | Generation of induced pluripotent stem cells from somatic cells.
Sohn YD, Han JW, Yoon YS. Prog Mol Biol Transl Sci. 2012;111:1-26. doi: 10.1016/B978-0-12-398459-3.00001-0. PMID: 22917224Review. |
| 41. | Role of bone marrow-derived lymphatic endothelial progenitor cells for lymphatic neovascularization.
Park C, Lee JY, Yoon YS. Trends Cardiovasc Med. 2011 Jul;21(5):135-40. doi: 10.1016/j.tcm.2012.04.002. PMID: 22732548Free PMC article.Review. |
| 42. | Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.
Lee S, Yoon YS. Br J Pharmacol. 2013 May;169(2):290-303. doi: 10.1111/j.1476-5381.2012.01857.x. PMID: 22250888Free PMC article.Review. |
| 43. | Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.
Kim H, Kim JJ, Yoon YS. Endocr Metab Immune Disord Drug Targets. 2012 Jun;12(2):168-78. doi: 10.2174/187153012800493486. PMID: 22236028Free PMC article.Review. |
| 44. | An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases.
Upadhyay AK, Rotili D, Han JW, Hu R, Chang Y, Labella D, Zhang X, Yoon YS, Mai A, Cheng X. J Mol Biol. 2012 Feb 24;416(3):319-27. doi: 10.1016/j.jmb.2011.12.036. Epub 2011 Dec 29. PMID: 22227394 Free PMC article. |
| 45. | Epigenetic landscape of pluripotent stem cells.
Han JW, Yoon YS. Antioxid Redox Signal. 2012 Jul 15;17(2):205-23. doi: 10.1089/ars.2011.4375. Epub 2012 Jan 11. PMID: 22044221Free PMC article.Review. |
| 46. | Overexpression of catalase in myeloid cells causes impaired postischemic neovascularization.
Hodara R, Weiss D, Joseph G, Velasquez-Castano JC, Landázuri N, Han JW, Yoon YS, Taylor WR. Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2203-9. doi: 10.1161/ATVBAHA.111.233247. Epub 2011 Jul 28. PMID: 21799178 Free PMC article. |
| 47. | Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells.
Szulwach KE, Li X, Li Y, Song CX, Han JW, Kim S, Namburi S, Hermetz K, Kim JJ, Rudd MK, Yoon YS, Ren B, He C, Jin P. PLoS Genet. 2011 Jun;7(6):e1002154. doi: 10.1371/journal.pgen.1002154. Epub 2011 Jun 23. PMID: 21731508 Free PMC article. |
| 48. | Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy.
Kim SW, Kim H, Yoon YS. Regen Med. 2011 May;6(3):335-49. doi: 10.2217/rme.11.24. PMID: 21548739 Free PMC article. |
| 49. | Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy.
Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, Kim DW, Yoon YS. Circ Res. 2011 May 27;108(11):1340-7. doi: 10.1161/CIRCRESAHA.110.239848. Epub 2011 Apr 14. PMID: 21493893 Free PMC article. |
| 50. | Induced pluripotent stem cells: emerging techniques for nuclear reprogramming.
Han JW, Yoon YS. Antioxid Redox Signal. 2011 Oct 1;15(7):1799-820. doi: 10.1089/ars.2010.3814. Epub 2011 May 5. PMID: 21194386Free PMC article.Review. |
| 51. | Tumor necrosis factor-α signaling via TNFR1/p55 is deleterious whereas TNFR2/p75 signaling is protective in adult infarct myocardium.
Kishore R, Tkebuchava T, Sasi SP, Silver M, Gilbert HY, Yoon YS, Park HY, Thorne T, Losordo DW, Goukassian DA. Adv Exp Med Biol. 2011;691:433-48. doi: 10.1007/978-1-4419-6612-4_45. PMID: 21153348Free PMC article.No abstract available. |
| 52. | Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization.
Lee JY, Park C, Cho YP, Lee E, Kim H, Kim P, Yun SH, Yoon YS. Circulation. 2010 Oct 5;122(14):1413-25. doi: 10.1161/CIRCULATIONAHA.110.941468. Epub 2010 Sep 20. PMID: 20855662 Free PMC article. |
| 53. | A hybrid biomimetic nanomatrix composed of electrospun polycaprolactone and bioactive peptide amphiphiles for cardiovascular implants.
Andukuri A, Kushwaha M, Tambralli A, Anderson JM, Dean DR, Berry JL, Sohn YD, Yoon YS, Brott BC, Jun HW. Acta Biomater. 2011 Jan;7(1):225-33. doi: 10.1016/j.actbio.2010.08.013. Epub 2010 Aug 20. PMID: 20728588 Free PMC article. |
| 54. | Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease.
Kim SW, Kim H, Cho HJ, Lee JU, Levit R, Yoon YS. J Am Coll Cardiol. 2010 Aug 10;56(7):593-607. doi: 10.1016/j.jacc.2010.01.070. PMID: 20688215 Free PMC article. |
| 55. | CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease.
Kim H, Cho HJ, Kim SW, Liu B, Choi YJ, Lee J, Sohn YD, Lee MY, Houge MA, Yoon YS. Circ Res. 2010 Sep 3;107(5):602-14. doi: 10.1161/CIRCRESAHA.110.218396. Epub 2010 Jul 15. PMID: 20634489 Free PMC article. |
| 56. | Autologous transplantation of endothelial progenitor cells genetically modified by adeno-associated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction.
Sen S, Merchan J, Dean J, Ii M, Gavin M, Silver M, Tkebuchava T, Yoon YS, Rasko JE, Aikawa R. Hum Gene Ther. 2010 Oct;21(10):1327-34. doi: 10.1089/hum.2010.006. PMID: 20497036 |
| 57. | True autologous approach in cell therapy. – Using your own serum for cell culture -.
Kim SW, Yoon YS. Circ J. 2010 May;74(5):852-3. doi: 10.1253/circj.cj-10-0301. Epub 2010 Apr 17. PMID: 20431230 Free PMC article. |
| 58. | Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy.
Kim H, Park JS, Choi YJ, Kim MO, Huh YH, Kim SW, Han JW, Lee J, Kim S, Houge MA, Ii M, Yoon YS. Stem Cells. 2009 Jul;27(7):1686-96. doi: 10.1002/stem.87. PMID: 19544451 Free PMC article. |
| 59. | Cell therapy with bone marrow cells for myocardial regeneration.
Kim H, Kim SW, Nam D, Kim S, Yoon YS. Antioxid Redox Signal. 2009 Aug;11(8):1897-911. doi: 10.1089/ars.2009.2486. PMID: 19203213Free PMC article.Review. |
| 60. | Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy.
Jeong JO, Kim MO, Kim H, Lee MY, Kim SW, Ii M, Lee JU, Lee J, Choi YJ, Cho HJ, Lee N, Silver M, Wecker A, Kim DW, Yoon YS. Circulation. 2009 Feb 10;119(5):699-708. doi: 10.1161/CIRCULATIONAHA.108.789297. Epub 2009 Jan 26. PMID: 19171856 Free PMC article. |
| 61. | Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis.
Tressel SL, Kim H, Ni CW, Chang K, Velasquez-Castano JC, Taylor WR, Yoon YS, Jo H. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1989-95. doi: 10.1161/ATVBAHA.108.175463. Epub 2008 Sep 4. PMID: 18772493 Free PMC article. |
| 62. | Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart.
Cho HJ, Lee N, Lee JY, Choi YJ, Ii M, Wecker A, Jeong JO, Curry C, Qin G, Yoon YS. J Exp Med. 2007 Dec 24;204(13):3257-69. doi: 10.1084/jem.20070166. Epub 2007 Dec 10. PMID: 18070934 Free PMC article. |
| 63. | Bone marrow-derived stem cell therapy in ischemic heart disease.
Cho HJ, Lee J, Wecker A, Yoon YS. Regen Med. 2006 May;1(3):337-45. doi: 10.2217/17460751.1.3.337. PMID: 17465787Review. |
| 64. | Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.
Kirchmair R, Tietz AB, Panagiotou E, Walter DH, Silver M, Yoon YS, Schratzberger P, Weber A, Kusano K, Weinberg DH, Ropper AH, Isner JM, Losordo DW. Mol Ther. 2007 Jan;15(1):69-75. doi: 10.1038/sj.mt.6300019. PMID: 17164777 |
| 65. | Derivation and characterization of bone marrow-derived multipotent stem cells.
Lee J, Wecker A, Losordo DW, Yoon YS. Exp Hematol. 2006 Nov;34(11):1602-3. doi: 10.1016/j.exphem.2006.07.012. PMID: 17046582No abstract available. |
| 66. | Synergism of hematopoietic cytokines for infarct repair.
Cho HJ, Yoon YS. Circ Res. 2006 Apr 28;98(8):990-2. doi: 10.1161/01.RES.0000222024.14452.7b. PMID: 16645148No abstract available. |
| 67. | Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury.
Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon YS, Wecker A, Luedemann C, Eaton E, Silver M, Thorne T, Losordo DW. Circ Res. 2006 Mar 17;98(5):697-704. doi: 10.1161/01.RES.0000209948.50943.ea. Epub 2006 Feb 16. PMID: 16484619 |
| 68. | Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization.
Qin G, Ii M, Silver M, Wecker A, Bord E, Ma H, Gavin M, Goukassian DA, Yoon YS, Papayannopoulou T, Asahara T, Kearney M, Thorne T, Curry C, Eaton L, Heyd L, Dinesh D, Kishore R, Zhu Y, Losordo DW. J Exp Med. 2006 Jan 23;203(1):153-63. doi: 10.1084/jem.20050459. Epub 2006 Jan 9. PMID: 16401693 Free PMC article. |
| 69. | Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling.
Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, Shintani S, Ii M, Asai J, Tkebuchava T, Thorne T, Takenaka H, Aikawa R, Goukassian D, von Samson P, Hamada H, Yoon YS, Silver M, Eaton E, Ma H, Heyd L, Kearney M, Munger W, Porter JA, Kishore R, Losordo DW. Nat Med. 2005 Nov;11(11):1197-204. doi: 10.1038/nm1313. Epub 2005 Oct 23. PMID: 16244652 |
| 70. | Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
Ii M, Nishimura H, Kusano KF, Qin G, Yoon YS, Wecker A, Asahara T, Losordo DW. Circulation. 2005 Jul 5;112(1):93-102. doi: 10.1161/CIRCULATIONAHA.104.511964. Epub 2005 Jun 27. PMID: 15983249 |
| 71. | Repair of ischemic heart disease with novel bone marrow-derived multipotent stem cells.
Lee N, Thorne T, Losordo DW, Yoon YS. Cell Cycle. 2005 Jul;4(7):861-4. doi: 10.4161/cc.4.7.1799. Epub 2005 Jul 4. PMID: 15970686Review. |
| 72. | The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A.
Kishore R, Qin G, Luedemann C, Bord E, Hanley A, Silver M, Gavin M, Yoon YS, Goukassian D, Losordo DW. J Clin Invest. 2005 Jul;115(7):1785-96. doi: 10.1172/JCI22849. Epub 2005 Jun 16. PMID: 15965500 Free PMC article. |
| 73. | Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia.
Bosch-Marcé M, Pola R, Wecker AB, Silver M, Weber A, Luedemann C, Curry C, Murayama T, Kearney M, Yoon YS, Malinow MR, Asahara T, Isner JM, Losordo DW. Vasc Med. 2005 Feb;10(1):15-22. doi: 10.1191/1358863x05vm585oa. PMID: 15920995 |
| 74. | Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.
Kirchmair R, Walter DH, Ii M, Rittig K, Tietz AB, Murayama T, Emanueli C, Silver M, Wecker A, Amant C, Schratzberger P, Yoon YS, Weber A, Panagiotou E, Rosen KM, Bahlmann FH, Adelman LS, Weinberg DH, Ropper AH, Isner JM, Losordo DW. Circulation. 2005 May 24;111(20):2662-70. doi: 10.1161/CIRCULATIONAHA.104.470849. Epub 2005 May 16. PMID: 15897348 |
| 75. | Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor.
Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R, Bahlman F, Walter D, Curry C, Hanley A, Isner JM, Losordo DW. Circulation. 2005 Apr 26;111(16):2073-85. doi: 10.1161/01.CIR.0000162472.52990.36. PMID: 15851615 |
| 76. | Cardiac regeneration with novel bone marrow-derived multipotent stem cells.
Yoon YS. Discov Med. 2005 Apr;5(26):204-8. PMID: 20704911 |
| 77. | Myocardial regeneration with bone-marrow-derived stem cells.
Yoon YS, Lee N, Scadova H. Biol Cell. 2005 Apr;97(4):253-63. doi: 10.1042/BC20040099. PMID: 15762847Review. |
| 78. | Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction.
Yoon YS, Wecker A, Heyd L, Park JS, Tkebuchava T, Kusano K, Hanley A, Scadova H, Qin G, Cha DH, Johnson KL, Aikawa R, Asahara T, Losordo DW. J Clin Invest. 2005 Feb;115(2):326-38. doi: 10.1172/JCI22326. PMID: 15690083 Free PMC article. |
| 79. | Therapeutic myocardial angiogenesis with vascular endothelial growth factors.
Yoon YS, Johnson IA, Park JS, Diaz L, Losordo DW. Mol Cell Biochem. 2004 Sep;264(1-2):63-74. doi: 10.1023/b:mcbi.0000044375.33928.62. PMID: 15544036Review. |
| 80. | Sonic hedgehog induces arteriogenesis in diabetic vasa nervorum and restores function in diabetic neuropathy.
Kusano KF, Allendoerfer KL, Munger W, Pola R, Bosch-Marce M, Kirchmair R, Yoon YS, Curry C, Silver M, Kearney M, Asahara T, Losordo DW. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2102-7. doi: 10.1161/01.ATV.0000144813.44650.75. Epub 2004 Sep 9. PMID: 15358602 |
| 81. | Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis.
Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford PW, Tietz AB, Kirchmair R, Silver M, Curry C, Wecker A, Yoon YS, Heidenreich R, Hanley A, Kearney M, Tio FO, Kuenzler P, Isner JM, Losordo DW. Circulation. 2004 Jul 6;110(1):36-45. doi: 10.1161/01.CIR.0000133324.38115.0A. Epub 2004 Jun 21. PMID: 15210598 |
| 82. | Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction.
Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Circulation. 2004 Jun 29;109(25):3154-7. doi: 10.1161/01.CIR.0000134696.08436.65. Epub 2004 Jun 14. PMID: 15197139 |
| 83. | Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction.
Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. J Clin Invest. 2004 Mar;113(6):885-94. doi: 10.1172/JCI20702. PMID: 15067321 Free PMC article. |
| 84. | All in the family: VEGF-B joins the ranks of proangiogenic cytokines.
Yoon YS, Losordo DW. Circ Res. 2003 Jul 25;93(2):87-90. doi: 10.1161/01.RES.0000084992.10766.36. PMID: 12881472No abstract available. |
| 85. | Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth.
Goukassian DA, Kishore R, Krasinski K, Dolan C, Luedemann C, Yoon YS, Kearney M, Hanley A, Ma H, Asahara T, Isner JM, Losordo DW. Circ Res. 2003 Jul 25;93(2):162-9. doi: 10.1161/01.RES.0000082980.94211.3A. Epub 2003 Jun 26. PMID: 12829616 |
| 86. | Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Behçet’s disease.
Kwon Koo B, Shim WH, Yoon YS, Kwon Lee B, Choi D, Jang Y, Lee DY, Chang BC. J Endovasc Ther. 2003 Feb;10(1):75-80. doi: 10.1177/152660280301000116. PMID: 12751935 |
| 87. | VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.
Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW. J Clin Invest. 2003 Mar;111(5):717-25. doi: 10.1172/JCI15830. PMID: 12618526 Free PMC article. |
| 88. | Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia.
Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, Uchida S, Masuo O, Iwaguro H, Ma H, Hanley A, Silver M, Kearney M, Losordo DW, Isner JM, Asahara T. Circulation. 2003 Jan 28;107(3):461-8. doi: 10.1161/01.cir.0000046450.89986.50. PMID: 12551872 |
| 89. | Treatment of thoracic aortic dissection with stent-grafts: midterm results.
Shim WH, Koo BK, Yoon YS, Choi D, Jang Y, Lee DY, Chang BC. J Endovasc Ther. 2002 Dec;9(6):817-21. doi: 10.1177/152660280200900615. PMID: 12546583 |
© 2021 KARIS BIO INC. ALL RIGHTS RESERVED